Identification and validation molecules and pathways responsible for relapse
About 75% of advanced epithelial ovarian cancer (EOC) patients respond to first-line surgery and chemotherapy but most relapse and ultimately acquire platinum resistance which soon leads to death.
Relapsed high grade serous ovarian cancer (HGSOC) is the single main cause of EOC-related morbidity and mortality. We hypothesize that the primary tumour includes a small population of resistant cells that are ultimately responsible for relapse. By targeting this population front-line we may prolong disease-free survival or even achieve cure. OCTIPS will use unique retrospective and novel prospective paired tumour samples collected at the time of diagnosis and relapse to identify and validate molecules and pathways responsible for relapse. This identification will employ high throughput multiplatform analyses such as next generation sequencing, mRNA and miRNA expression arrays and SNP array. Known and newly defined molecules or pathways will be evaluated in innovative integrated cancer model systems like cell lines, avian egg and murine xenografts. New therapies targeting these molecules and pathways will be developed and validated in model systems.
By translating the clinical observation of treatment failures into innovative cancer models that mimic relapsed ovarian cancer, we will validate improved front-line therapeutic strategies to help prolong patient survival.
Researchers of the Medical University
The Medical University of Vienna is project coordinator under the leadership of Ao. Univ.-Prof. Dr. Dan Cacsire Castillo-Tong, Department of Obstetrics and Gynecology.
Further participating department at the edical University of Vienna:
Ao. Univ.-Prof. Georg Heinze, CeMSIIS, Institut für Klinische Biometrie
Project coordinator: Ao. Univ.-Prof. Dr. Dan Cacsire Castillo-Tong, Universitätsklinik für Frauenheilkunde, MedUni Vienna
Project partners: 11
|Topic||HEALTH.2011.2.4.1-2: Translational research on cancers with poor prognosis, FP7-HEALTH-2011-two-stage|
|Project duration||01.01.2012 - 31.12.2015|
|Funding volume, total||2.999.302 €|
|Funding volume, Medical University of Vienne||533.492 €|